<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Roflumilast (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Roflumilast (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Roflumilast (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="139317" href="/d/html/139317.html" rel="external">see "Roflumilast (topical): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="139289" href="/d/html/139289.html" rel="external">see "Roflumilast (topical): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57118916"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zoryve</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58248917"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zoryve</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57073563"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphodiesterase-4 Enzyme Inhibitor, Topical;</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F57083941"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis: Topical:</b> Cream: Apply once daily to affected areas.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66302c89-8cc8-49f7-a54e-522f64125112">Seborrheic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seborrheic dermatitis: Topical:</b> Foam: Apply once daily to affected areas.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57083943"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F57083944"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Child-Turcotte-Pugh class A: No dosage adjustment needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Child-Turcotte-Pugh class B and C: Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F57083942"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57083555"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139289" href="/d/html/139289.html" rel="external">see "Roflumilast (topical): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b> Children ≥6 years and Adolescents: 0.3% cream: Topical: Apply to affected area(s) once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57083556"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F57083557"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F57087336"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (≤3%), nausea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (1% to 2%), insomnia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (2%), upper respiratory tract infection (1%)</p></div>
<div class="block coi drugH1Div" id="F57073566"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe liver impairment (Child-Turcotte-Pugh class B or C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to roflumilast or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57083933"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Foam: Foam contains flammable propellants. Avoid fire, flame, and smoking during and immediately following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For topical use only; not for ophthalmic, oral, or intravaginal use.</p></div>
<div class="block foc drugH1Div" id="F57118917"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoryve: 0.3% (60 g) [contains cetostearyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoryve: 0.3% (60 g) [contains cetyl alcohol, methylparaben, propylparaben]</p></div>
<div class="block geq drugH1Div" id="F57118915"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57150382"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Zoryve External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3% (per gram): $17.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Zoryve External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3% (per gram): $17.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58248918"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoryve: 0.3% (5 g, 60 g) [contains cetostearyl alcohol, methylparaben, propylparaben]</p></div>
<div class="block adm drugH1Div" id="F57083945"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> For topical use only; not for ophthalmic, oral, or intravaginal use. Wash hands after use, unless treating the hands.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Rub in completely.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Shake well prior to use. Apply a thin layer to dry skin and/or scalp; rub in completely. Avoid fire, flame, and smoking during and immediately following use.</p></div>
<div class="block admp drugH1Div" id="F57083558"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For topical use only; not for ophthalmic, oral, or intravaginal use. Rub cream in completely to affected area(s). Wash hands following application unless using for treatment of psoriasis on hands.</p></div>
<div class="block use drugH1Div" id="F57073565"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b> Cream: Treatment of plaque psoriasis, including intertriginous areas, in adults and pediatric patients ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seborrheic dermatitis:</b> Foam: Treatment of seborrheic dermatitis in adult and pediatric patients ≥9 years of age.</p></div>
<div class="block cyt drugH1Div" id="F57087448"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F57087445"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Cimetidine may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol-Containing Products: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Ethinyl Estradiol-Containing Products may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. FluvoxaMINE may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Roflumilast-Containing Products may enhance the hypotensive effect of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Viloxazine may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F57083931"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with topical roflumilast.</p></div>
<div class="block brc drugH1Div" id="F57083932"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if roflumilast is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Breastfeeding patients should treat the smallest area for the shortest duration possible and should not apply roflumilast to the nipple and areola area to avoid direct infant exposure.</p></div>
<div class="block pha drugH1Div" id="F57083936"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Roflumilast and its active N-oxide metabolite selectively inhibit phosphodiesterase-4 (PDE4), leading to accumulation of cyclic AMP (cAMP). The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.</p></div>
<div class="block phk drugH1Div" id="F57083937"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%; N-oxide metabolite: 97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 and CYP1A2 to active N-oxide metabolite; also undergoes conjugation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3.6 to 4 days; N-oxide metabolite: 4.4 to 4.6 days.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Zoryve cream (roflumilast) [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics Inc; October 2023.</div>
</li>
<li>
<div class="reference">
                  Zoryve foam (roflumilast) [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics Inc; December 2023.</div>
</li>
<li>
<div class="reference">
                  Zoryve (roflumilast) [product monograph]. Burlington, Ontario, Canada: CRI; November 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 139287 Version 31.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
